Abstract:Aim: Human histone deacetylase 8 (KDAC8) is a well-recognized pharmaceutical target in Cornelia de Lange syndrome and different types of cancer, particularly childhood neuroblastoma. Several classes of chemotypes have been identified, which interfere with the enzyme activity of KDAC8. These compounds have been identified under equilibrium or near equilibrium conditions for inhibitor binding to the target enzyme. This study aims for the classification of KDAC8 inhibitors according to the mode of action and identification of most promising lead compounds for drug development. Methods: A continuous enzyme activity assay is used to monitor inhibition kinetics. Results: A high-throughput continuous KDAC8 activity assay is developed that provides additional mechanistic information about enzyme inhibition enabling the classification of KDAC8 inhibitors according to their mode of action. Fast reversible inhibitors act as a molecular chaperone and are capable to rescue the enzyme activity of misfolded KDAC8, while covalent inactivators and slow dissociating inhibitors do not preserve KDAC8 activity. Conclusions: The application of continuous KDAC8 activity assay reveals additional information about the mode of interaction with inhibitors, which can be used to classify KDAC8 inhibitors according to their mode of action. The approach is compatible with the high-throughput screening of compound libraries. Fast reversible inhibitors of KDAC8 act as molecular chaperones and recover enzyme activity from misfolded protein conformations. In contrast, slow-binding inhibitors and covalent inactivators of KDAC8 are not capable to recover enzyme activity.

Chemoprobe-based Assays of Histone Lysine Demethylase 1A Target Occupation Enable in Vivo Pharmacokinetics and Pharmacodynamics Studies of KDM1A Inhibitors

Development of homogeneous nonradioactive methyltransferase and demethylase assays targeting histone H3 lysine 4

Development of substrate-selective probes for affinity pulldown of histone demethylases.

KDM1 histone lysine demethylases as targets for treatments of oncological and neurodegenerative disease

Label-free in situ monitoring of histone deacetylase drug target engagement by matrix-assisted laser desorption ionization-mass spectrometry biotyping and imaging

Targeting N‐methyl‐lysine histone demethylase KDM4 in cancer: natural products inhibitors as a driving force for epigenetic drug discovery

Structural Simulation and Selective Inhibitor Discovery Study for Histone Demethylases KDM4E/6B from a Computational Perspective

Fluorometric and Colorimetric Dual-Readout Assay for Histone Demethylase Activity Based on Formaldehyde Inhibition of Ag+-Triggered Oxidation of O-Phenylenediamine.

Continuous enzyme activity assay for high-throughput classification of histone deacetylase 8 inhibitors

Identification of the KDM2/7 Histone Lysine Demethylase Subfamily Inhibitor and Its Antiproliferative Activity.

Discovery of an in Vivo Chemical Probe of the Lysine Methyltransferases G9a and GLP

Pharmacological inhibition of KDM5A for cancer treatment

An In-Line Capillary Electrophoresis Assay for the High-Throughput Screening of Histone Deacetylase Inhibitors.

Identification of potent, selective KDM5 inhibitors.

A novel screening strategy to identify histone methyltransferase inhibitors reveals a crosstalk between DOT1L and CARM1

Structure-guided design of a selective inhibitor of the methyltransferase KMT9 with cellular activity

High-Throughput-Methyl-Reading (HTMR) Assay: a Solution Based on Nucleotide Methyl-Binding Proteins Enables Large-Scale Screening for DNA/RNA Methyltransferases and Demethylases

Novel Scaffolds of Cell-Active Histone Demethylase Inhibitors Identified from High-Throughput Screening.

Development of High-Throughput Assays for Evaluation of Hematopoietic Progenitor Kinase 1 Inhibitors

A Direct Assay for Measuring the Activity and Inhibition of Coactivator-Associated Arginine Methyltransferase 1

Discovery of Pyrazolo[1,5-A]pyrimidine-3-carbonitrile Derivatives As a New Class of Histone Lysine Demethylase 4D (KDM4D) Inhibitors.